Collegium Pharmaceutical (COLL) is back in focus after reporting first quarter 2026 earnings that showed a sharp jump in profitability and progress across its ADHD and pain portfolios, alongside a proposed AZSTARYS acquisition.

Despite the strong first quarter earnings and the proposed AZSTARYS deal, Collegium Pharmaceutical’s share price performance has been mixed. The 7 day share price return was 9.31%, but the 90 day share price return fell 19.14%. However, the 1 year total shareholder return of 27.88% and 3 year total shareholder return of 60.85% point to stronger longer term momentum.

If this kind of earnings driven move has your attention, it could be a good time to broaden your search and check out 34 healthcare AI stocks

With earnings ahead of expectations, annual net income growth above 40%, and a forward P/E of 5.84 at a last close of US$37.80, is Collegium undervalued or is the market already pricing in its future growth?

Most Popular Narrative: 30.2% Undervalued

Collegium Pharmaceutical's most followed valuation narrative points to a fair value around $54.17 versus the last close of $37.80, setting up a wide gap for investors to assess.

Collegium is positioned to benefit from broadening demand for specialty pharmaceuticals addressing chronic medical conditions, as seen in the successful integration and rapid growth trajectory of Jornay PM, a product with expanding use among both adult and pediatric patient populations. This underappreciated expansion directly supports revenue and total earnings growth.

Interested in how a relatively flat revenue outlook can still back a sharply higher earnings profile and a higher fair value? The narrative leans heavily on margin expansion, disciplined capital use, and a lower future earnings multiple than many peers. The full breakdown shows how these moving parts are stitched together into that valuation story.

Using a 7.0% discount rate, this most popular narrative anchors on a fair value of $54.17, which is about 30.2% above the recent $37.80 share price, and wraps in assumptions about steady top line, rising profitability, and a future P/E that sits below the current US pharmaceuticals average.

Result: Fair Value of $54.17 (UNDERVALUED)

However, that upside story still relies on optimistic margin assumptions, while patent expiries and potential generic competition in the pain portfolio could quickly weaken it.

Another Angle: What Do The Earnings Multiples Say?

While the popular narrative leans on a fair value of $54.17, today Collegium trades on a P/E of about 16.4x versus the US Pharmaceuticals industry at 16.1x and a peer average of 71.3x. The fair ratio sits higher at 24.3x, which suggests potential for multiple expansion. It also raises the question of how much earnings risk you are comfortable with if sentiment cools.

Next Steps

With mixed signals across earnings, valuation, and sentiment, the picture is not straightforward. Consider reviewing the data yourself promptly and weighing both the upside and the downside using 4 key rewards and 1 important warning sign

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop with one stock. Use these focused idea lists to quickly spot opportunities others might overlook.

• Target potential value opportunities by scanning companies that appear mispriced on quality and fundamentals through the 49 high quality undervalued stocks.
• Strengthen your core holdings by focusing on companies with healthier finances using the solid balance sheet and fundamentals stocks screener (44 results).
• Get ahead of the crowd by hunting for promising smaller companies with robust metrics in the screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.